Senores Pharmaceuticals Ltd (SENORES) — FY26 Annual Report | 3 September 2026 (2 announcements)

Senores Pharmaceuticals Ltd (SENORES) held its 9th AGM on September 25, 2026, approving key governance and financial matters including the appointment of Viranchi Arvindbhai Shah as an Independent Director, approval of the Employee Stock Option Scheme 2026, and revisions to director remuneration. The company reported robust FY2025-26 performance with 62% YoY revenue growth to [amount context mismatch] Cr, 108% PAT growth to [amount context mismatch] Cr, and 385% growth in domestic Branded Generics. Strategic focus areas include expansion in regulated markets (70% of revenue), USFDA-approved facilities, and acquisitions like Apnar Pharma and Zoraya. The AGM also covered resolutions on fund utilization, CSR compliance, and shareholding patterns, with no dividend recommended for FY2025-26.

Senores Pharmaceuticals Ltd reported a 62% YoY revenue surge to [amount context mismatch] Cr in FY2025-26, driven by a doubled ANDA portfolio (51 approved products) and expansion into US federal supply chains via Amerisyn and Zoraya. The company achieved 108% YoY growth in patented generics (patG) to [amount context mismatch] Cr, with cash flow from operations at ₹75 Cr. Strategic focus includes capacity expansion (1.2B to 1.5B US solid-dose units), API facility scaling (25 MTPA to 169 MTPA), and EBITDA margin targets of 18%-21% in emerging markets. Key growth drivers are regulated market dominance (70% revenue share), 478 emerging market products, and 27 pipeline molecules. The company secured USFDA approvals, WHO-GMP compliance, and launched 75 CDMO/CMO products. It also acquired Apnar Pharma (75% for ₹91 Cr) and Zoraya Pharmaceuticals (51% stake), while implementing SAP S/4HANA Cloud for operational integration.